All In Biotech

Drug Trial Radar · NCT06196632

Development and Validation of Models to Predict Functional Cure in Patients With CHB After Peg-IFN Based Therapy

Development and Validation of Logistic Regression Models to Predict Durable Functional Cure in Patients With Chronic Hepatitis B After Pegylated Interferon Alpha-2b Based Therapy

Last checked: Nov 19, 2026Latest source record: Feb 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Jan 6, 2024

Primary completion

Jul 31, 2024

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Qilu Hospital of Shandong UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 9, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 16 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hepatitis B virus (HBV) infection is prevalent across the world. Functional cure is the optimal endpoint of antiviral therapy for chronic hepatitis B virus (HBV) infection. Currently available anti-HBV therapy includes nucleoside analogs (NAs) and peginterferon-α (Peg-IFNα). Combination of Peg-IFNα and NAs, each with different mechanisms of action, is an attractive approach for treating chronic HBV infection. In this study, we aim to establish logistic regression models to predict durable functional cure in patients with CHB treated by combination of Peg-IFNα and NAs, which might be useful for clinical physicians to make personalized treatment decisions. These models will be constructed using baseline routine clinical laboratory indicators with high diagnostic accuracy. These models might be widely applicable to almost all medical institutions and will effectively promote the application of Peg IFN α plus NAs therapy in clinical work. The findings in this study might greatly improve the functional cure rate of CHB and reducing the incidence rate and mortality of HBV related end-stage liver diseases.

Conditions

  • Hepatitis B, Chronic

Interventions

  • Peginterferon-α; Nucleoside analogsDrug

    Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Functional cure of chronic hepatit BTime frame: 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Qilu hospital of Shandong University

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.